Kinase inhibitors in the treatment of obstructive pulmonary diseases.
Journal
Current opinion in pharmacology
ISSN: 1471-4973
Titre abrégé: Curr Opin Pharmacol
Pays: England
ID NLM: 100966133
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
10
01
2020
revised:
10
03
2020
accepted:
26
03
2020
pubmed:
4
5
2020
medline:
10
8
2021
entrez:
4
5
2020
Statut:
ppublish
Résumé
Chronic pulmonary diseases, including chronic obstructive pulmonary disease (COPD) and asthma, are major causes of death and reduced quality of life. Characteristic of chronic pulmonary disease is excessive lung inflammation that occurs in response to exposure to inhaled irritants, chemicals, and allergens. Chronic inflammation leads to remodeling of the airways that includes excess mucus secretion, proliferation of smooth muscle cells, increased deposition of extracellular matrix proteins and fibrosis. Protein kinases have been implicated in mediating inflammatory signals and airway remodeling associated with reduced lung function in chronic pulmonary disease. This review will highlight the role of protein kinases in the lung during chronic inflammation and examine opportunities to use protein kinase inhibitors for the treatment of chronic pulmonary diseases.
Identifiants
pubmed: 32361678
pii: S1471-4892(20)30008-4
doi: 10.1016/j.coph.2020.03.005
pmc: PMC8504404
mid: NIHMS1743973
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-18Subventions
Organisme : NIAID NIH HHS
ID : R21 AI126492
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM066706
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Pharmacol Rev. 2016 Jul;68(3):788-815
pubmed: 27363440
PLoS One. 2018 Mar 22;13(3):e0194197
pubmed: 29566026
Drug Discov Today. 2011 Dec;16(23-24):1084-91
pubmed: 21930234
Clin Ther. 2019 Jun;41(6):1214-1220
pubmed: 31076203
Front Pharmacol. 2018 Jan 31;9:54
pubmed: 29445342
Respir Med. 2017 Sep;130:20-26
pubmed: 29206629
Lancet Respir Med. 2017 Sep;5(9):691-706
pubmed: 28822787
Curr Opin Pharmacol. 2019 Jun;46:73-81
pubmed: 31078066
Eur J Pharmacol. 2008 May 13;585(2-3):398-406
pubmed: 18410919
Eur Respir J. 2005 Jun;25(6):978-85
pubmed: 15929951
Int Immunopharmacol. 2005 Mar;5(3):495-502
pubmed: 15683846
Ophthalmology. 2018 Nov;125(11):1741-1756
pubmed: 30007591
Curr Med Chem. 2019;26(16):2791-2800
pubmed: 29557740
J Exp Med. 1999 Nov 1;190(9):1309-18
pubmed: 10544202
Exp Lung Res. 2010 May;36(4):201-10
pubmed: 20426528
Curr Opin Pulm Med. 2016 Jan;22(1):46-52
pubmed: 26574718
Am J Respir Cell Mol Biol. 2006 Jun;34(6):695-703
pubmed: 16456186
Am J Physiol Lung Cell Mol Physiol. 2007 Apr;292(4):L1023-9
pubmed: 17189320
Pharmacol Ther. 2018 May;185:155-169
pubmed: 29287707
J Allergy Clin Immunol. 2000 Feb;105(2 Pt 2):S527-34
pubmed: 10669537
Int J Chron Obstruct Pulmon Dis. 2018 Dec 20;14:81-91
pubmed: 30587964
Exp Lung Res. 2018 May - Jun;44(4-5):217-225
pubmed: 30468094
PLoS One. 2015 Sep 03;10(9):e0136065
pubmed: 26336076
Expert Rev Respir Med. 2016;10(3):339-50
pubmed: 26855301
JCI Insight. 2018 Aug 23;3(16):
pubmed: 30135301
Expert Opin Emerg Drugs. 2003 May;8(1):71-81
pubmed: 14610913
Proc Am Thorac Soc. 2008 Jan 1;5(1):89-96
pubmed: 18094090
J Immunol. 2017 Apr 15;198(8):3296-3306
pubmed: 28298524
Pulm Pharmacol Ther. 2017 Oct;46:69-77
pubmed: 28823947
Immunity. 2019 Apr 16;50(4):975-991
pubmed: 30995510
Allergy. 2019 Jul;74(7):1249-1256
pubmed: 30834543
Mol Carcinog. 2019 Sep;58(9):1551-1570
pubmed: 31190430
Nat Immunol. 2003 Apr;4(4):313-9
pubmed: 12660731
Cell Commun Adhes. 2013 Feb;20(1-2):21-40
pubmed: 23472830
J Med Chem. 2012 Nov 26;55(22):10090-107
pubmed: 23061660
Int J Mol Sci. 2019 Mar 26;20(6):
pubmed: 30917554
Nat Rev Immunol. 2018 Jul;18(7):454-466
pubmed: 29626211
JAMA. 2017 Jul 18;318(3):279-290
pubmed: 28719697
Sci Transl Med. 2018 Nov 21;10(468):
pubmed: 30463918
J Allergy Clin Immunol. 2018 Mar;141(3):1122-1124.e11
pubmed: 29079133
J Clin Invest. 2002 May;109(10):1279-83
pubmed: 12021241
Pulm Circ. 2018 Jan-Mar;8(1):2045893217739807
pubmed: 29040010
Can J Physiol Pharmacol. 1997 Jul;75(7):898-910
pubmed: 9315359
J Med Chem. 2013 Jun 13;56(11):4764-85
pubmed: 23659214
J Allergy Clin Immunol. 2002 Jan;109(1):75-81
pubmed: 11799369
Lab Invest. 2006 Sep;86(9):867-72
pubmed: 16865089
Mol Endocrinol. 1999 Feb;13(2):276-85
pubmed: 9973257
Biochem Biophys Res Commun. 2019 Aug 20;516(2):571-577
pubmed: 31235256
FASEB J. 2019 Oct;33(10):10833-10843
pubmed: 31266368
Mucosal Immunol. 2012 Mar;5(2):140-9
pubmed: 22189956
Int J Chron Obstruct Pulmon Dis. 2018 Mar 27;13:1009-1019
pubmed: 29628759
Environ Toxicol. 2019 Apr;34(4):476-485
pubmed: 30623574
Curr Med Chem. 2009;16(29):3875-85
pubmed: 19747135
J Leukoc Biol. 2012 Apr;91(4):557-69
pubmed: 22293472
J Allergy Clin Immunol. 2006 Aug;118(2):368-75
pubmed: 16890760
Br J Pharmacol. 2003 Dec;140(8):1373-80
pubmed: 14623764
Pharmacol Rep. 2017 Aug;69(4):746-756
pubmed: 28582691
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582
pubmed: 28128970
Eur Respir J Suppl. 2001 Dec;34:50s-59s
pubmed: 12392035
Curr Drug Targets. 2019;20(4):367-379
pubmed: 30112991
J Med Chem. 2019 Oct 24;62(20):9045-9060
pubmed: 31609613
Mucosal Immunol. 2013 Mar;6(2):335-46
pubmed: 22892938
N Engl J Med. 2017 May 18;376(20):1911-1920
pubmed: 28514613
Allergy. 2009 Aug;64(8):1194-201
pubmed: 19614621
Respir Med. 2019 Sep;156:33-46
pubmed: 31421589
Nat Rev Drug Discov. 2003 Sep;2(9):717-26
pubmed: 12951578
Am J Respir Crit Care Med. 2010 Mar 1;181(5):438-45
pubmed: 20007923